InspireMD (NSPR) CFO receives 226,695 restricted stock units grant

Rhea-AI Filing Summary

InspireMD, Inc. reported an equity grant to its Chief Financial Officer. A Form 4 shows CFO Michael Lawless received an award of 226,695 shares of common stock on January 14, 2026 at a price of $0 per share, increasing his directly held stake to 691,695 shares.

The new shares are restricted stock that vest in three equal annual installments, with one-third vesting on each of January 14, 2027, January 14, 2028, and January 14, 2029, as long as he continues in service with the company.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lawless Michael A

(Last) (First) (Middle)

C/O INSPIREMD, INC.

6303 WATERFORD DISTRICT DRIVE, SUITE 215

(Street)

MIAMI FL 33126

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
InspireMD, Inc. [ NSPR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/14/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/14/2026		A		226,695(1)	A	$0	691,695	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares of common stock represent shares of restricted stock, which vest and become exercisable in three equal annual installments, with 1/3 vesting on each of January 14, 2027, January 14, 2028 and January 14, 2029, subject to the Reporting Person's continued service.

Remarks:

Exhibit 24.1: Power of Attorney

	/s/ Michael Lawless	01/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did InspireMD (NSPR) disclose in this Form 4?

The filing discloses that InspireMD Chief Financial Officer Michael Lawless was awarded 226,695 shares of common stock on January 14, 2026 at a price of $0 per share.

Who is the reporting person in the InspireMD (NSPR) Form 4?

The reporting person is Michael A. Lawless, who serves as Chief Financial Officer of InspireMD, Inc.

How many InspireMD (NSPR) shares does the CFO hold after this grant?

After the reported transaction, Michael Lawless beneficially owns 691,695 shares of InspireMD common stock in direct ownership.

What type of shares were granted to the InspireMD (NSPR) CFO?

The grant consists of restricted shares of common stock, awarded at no cash cost to the CFO and subject to a service-based vesting schedule.

What is the vesting schedule for the 226,695 InspireMD (NSPR) restricted shares?

The 226,695 restricted shares vest in three equal annual installments, with 1/3 vesting on each of January 14, 2027, January 14, 2028, and January 14, 2029, contingent on continued service.

Is the InspireMD (NSPR) CFO’s ownership direct or indirect in this Form 4?

The Form 4 indicates the CFO’s 691,695 shares of common stock are held with direct (D) ownership.